Abstract:Immune checkpoint inhibitors (ICIs) have dramatically changed the way we treat advanced non-small cell lung cancer (NSCLC). Compared to chemotherapy alone, ICIs significantly improve overall survival, and these survival benefits are durable. Unfortunately, only a minority of patients benefit from ICI therapy. Most advanced NSCLC patients are non-responders. Several factors may contribute to poor response rates. One, we may not be correctly identifying the patients who could benefit from ICIs. Currently, PD-L1 is the only predictive biomarker; yet not all tumors that express PD-L1 are responsive. Two, blocking checkpoints to restore cytotoxic T lymphocyte (CTL) function may be insufficient to cure disease. The tumor microenvironment (TME) likely remains hostile to CTLs even after ICI therapy. The TME may continue inhibiting infiltrated CTLs or may prevent CTL infiltration in the first place. To effectively re- invigorate CTL-mediated anti-tumor responses, we must remodel the TME into one that is hospitable for CTLs; however, our understanding of the TME is limited. Here, we demonstrate the use of spatial transcriptomics to (1) identify novel predictive biomarkers for ICI therapy, and (2) generate a comprehensive profile of the NSCLC TME. Using Nanostring's GeoMX Digital Spatial Profiler (DSP), we performed spatial analysis on 56 human NSCLC tumors. Using the DSP's state-of-the-art UV masking technology, we generated transcriptomic profiles of CD8+ CTLs, the vimentin+ stroma, and the vimentin- tumor. We grouped the profiles of each compartment using their inflammatory status—hot/inflamed, or cold/not-inflamed—to identify differentially expressed genes that correspond to the immune phenotype of the tumors. We identified 112 DEGs in CD8+T cells and found that T cells in cold tumors were functional but poorly migratory. Strikingly, T cells in hot tumors were dysfunctional but motile and able to infiltrate tumors. 41 DEGs were identified in the Vimentin+ stroma. The stroma of hot tumors was enriched in CEACAM1, HMGB1, and LGALS9—all ligands of TIM3, a known immune checkpoint. The stroma of cold tumors expressed higher levels of JAG2, LTB4R, and SEMA4C. Bioinformatic analysis of TCGA data indicated that all three molecules are negatively correlated with CD8A levels in NSCLC tumors, which suggests that these molecules could promote T cell exclusion. 29 DEGs were identified in the tumor, and hot tumors were enriched in pathways associated with cellular migration and inhibition of immune effectors. In depth analysis of molecules upregulated in cold T cells revealed five new potential predictive biomarkers. CD2, CD52, KLRK1, NKG7, and PTPRC are upregulated in responders, and higher expression of these molecules corresponded to improved response to anti-PD1 therapy. In sum, our innovative studies highlight the utility of spatial transcriptomics in profiling the TME and identify new biomarkers that could be used to predict response to ICI therapy. Citation Format: Christina Cho, Francesc Lopez, Gavitt Woodard, Baozhu Huang, Jianwei He, Tayf Badri, Michal Kidacki, Matthew Vesely, Evelyn Ng, Guilin Wang, Lieping Chen. Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-08.

Spatially informed gene signatures for response to immunotherapy in melanoma

Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature.

Abstract 1141: Spatial-specific gene signatures to predict immunotherapy outcomes in lung cancer

Spatially Resolved Analyses Link Genomic and Immune Diversity and Reveal Unfavorable Neutrophil Activation in Melanoma

Spatial assessment of stromal B cell aggregates predicts response to checkpoint inhibitors in unresectable melanoma

Machine learning-based identification of an immunotherapy-related signature to enhance outcomes and immunotherapy responses in melanoma

The Prognostic Landscape of Adaptive Immune Resistance Signatures and Infiltrating Immune Cells in the Tumor Microenvironment of Uveal Melanoma.

Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging

Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment

Spatially mapping the immune landscape of melanoma using imaging mass cytometry

A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies

Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade

Multi‐omic and spatial dissection of immunotherapy response groups in non‐small cell lung cancer

Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma

Multiplexed Imaging Mass Cytometry Reveals Distinct Tumor-Immune Microenvironments Linked to Immunotherapy Responses in Melanoma

Abstract 1154: Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy response

Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients

Mapping the single cell spatial immune landscapes of the melanoma microenvironment

Spatial resolution of the head and neck cancer tumor microenvironment to identify tumor and stromal features associated with therapy response

Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy

Abstract 583: Spatiotemporal analyses of longitudinal specimens reveal mechanisms of response and resistance to immune checkpoint blockade in metastatic melanoma